Recursion Pharmaceuticals (NASDAQ:RXRX) Announces Quarterly Earnings Results

Recursion Pharmaceuticals (NASDAQ:RXRX) announced its earnings results on Monday. The company reported ($0.22) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.22), FiscalAI reports. Recursion Pharmaceuticals had a negative net margin of 945.94% and a negative return on equity of 50.41%. The business had revenue of $18.55 million during the quarter, compared to analyst estimates of $14.81 million.

Recursion Pharmaceuticals Trading Down 5.0%

Shares of Recursion Pharmaceuticals stock traded down $0.20 during trading on Monday, reaching $3.83. 22,519,947 shares of the stock were exchanged, compared to its average volume of 19,653,457. The company has a quick ratio of 5.03, a current ratio of 5.03 and a debt-to-equity ratio of 0.01. The firm has a market cap of $2.05 billion, a price-to-earnings ratio of -3.68 and a beta of 1.15. Recursion Pharmaceuticals has a 1 year low of $2.77 and a 1 year high of $5.76. The stock’s fifty day moving average is $3.74 and its 200 day moving average is $3.54.

Insider Activity at Recursion Pharmaceuticals

In other Recursion Pharmaceuticals news, Director Robert Hershberg sold 25,000 shares of the company’s stock in a transaction that occurred on Tuesday, October 6th. The stock was sold at an average price of $5.00, for a total transaction of $125,000.00. Following the completion of the transaction, the director owned 162,156 shares of the company’s stock, valued at $810,780. This represents a 13.36% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Blake Borgeson sold 50,000 shares of the stock in a transaction that occurred on Tuesday, October 6th. The stock was sold at an average price of $4.84, for a total value of $242,000.00. Following the completion of the sale, the director owned 6,108,287 shares of the company’s stock, valued at approximately $29,564,109.08. This trade represents a 0.81% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 157,408 shares of company stock worth $643,576 in the last 90 days. Company insiders own 6.65% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of brokerages have recently commented on RXRX. Needham & Company LLC reissued a “buy” rating and issued a $8.00 price target on shares of Recursion Pharmaceuticals in a report on Monday, October 19th. Morgan Stanley set a $5.90 price objective on shares of Recursion Pharmaceuticals in a report on Friday, October 16th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Recursion Pharmaceuticals in a research note on Thursday, October 15th. Finally, Wall Street Zen upgraded shares of Recursion Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research report on Saturday, October 17th. Two analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, Recursion Pharmaceuticals has a consensus rating of “Hold” and a consensus target price of $8.18.

Recursion Pharmaceuticals Company Profile

Recursion Pharmaceuticals, Inc is a biotechnology company that uses advanced computing, artificial intelligence and automated biology to discover and develop new medicines. The company’s platform, known as the Recursion Operating System, combines large-scale biological experimentation with machine learning and data analysis to identify potential drug candidates and characterize how diseases respond to treatments.

Recursion applies its technology to a range of therapeutic areas, including oncology, rare diseases, neuroscience and infectious diseases.